These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 38562891)

  • 1. Incretin hormones and pharmacomimetics rapidly inhibit AgRP neuron activity to suppress appetite.
    McMorrow HE; Lorch CM; Hayes NW; Fleps SW; Frydman JA; Xia JL; Samms RJ; Beutler LR
    bioRxiv; 2024 Mar; ():. PubMed ID: 38562891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
    Nauck MA; Quast DR; Wefers J; Pfeiffer AFH
    Diabetes Obes Metab; 2021 Sep; 23 Suppl 3():5-29. PubMed ID: 34310013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin hormones: Their role in health and disease.
    Nauck MA; Meier JJ
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AgRP Neurons Can Increase Food Intake during Conditions of Appetite Suppression and Inhibit Anorexigenic Parabrachial Neurons.
    Essner RA; Smith AG; Jamnik AA; Ryba AR; Trutner ZD; Carter ME
    J Neurosci; 2017 Sep; 37(36):8678-8687. PubMed ID: 28821663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.
    Campbell JE
    Mol Metab; 2021 Apr; 46():101139. PubMed ID: 33290902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological antagonism of the incretin system protects against diet-induced obesity.
    Svendsen B; Capozzi ME; Nui J; Hannou SA; Finan B; Naylor J; Ravn P; D'Alessio DA; Campbell JE
    Mol Metab; 2020 Feb; 32():44-55. PubMed ID: 32029229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.
    Tan Q; Akindehin SE; Orsso CE; Waldner RC; DiMarchi RD; Müller TD; Haqq AM
    Front Endocrinol (Lausanne); 2022; 13():838410. PubMed ID: 35299971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of independent and combined effects of the neurotensin receptor agonist, JMV-449, and incretin mimetics on pancreatic islet function, glucose homeostasis and appetite control.
    Craig SL; Gault VA; Shiels CE; Hamscher G; Irwin N
    Biochim Biophys Acta Gen Subj; 2021 Aug; 1865(8):129917. PubMed ID: 33964357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incretin hormones regulate microglia oxidative stress, survival and expression of trophic factors.
    Spielman LJ; Gibson DL; Klegeris A
    Eur J Cell Biol; 2017 May; 96(3):240-253. PubMed ID: 28336086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity pharmacotherapy: incretin action in the central nervous system.
    Boer GA; Hay DL; Tups A
    Trends Pharmacol Sci; 2023 Jan; 44(1):50-63. PubMed ID: 36462999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
    Hansotia T; Drucker DJ
    Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
    Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
    Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incretin hormones and type 2 diabetes.
    Nauck MA; Müller TD
    Diabetologia; 2023 Oct; 66(10):1780-1795. PubMed ID: 37430117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New physiological effects of the incretin hormones GLP-1 and GIP.
    Asmar M
    Dan Med Bull; 2011 Feb; 58(2):B4248. PubMed ID: 21299928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretin Hormones and Type 2 Diabetes-Mechanistic Insights and Therapeutic Approaches.
    Boer GA; Holst JJ
    Biology (Basel); 2020 Dec; 9(12):. PubMed ID: 33339298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation.
    Yabe D; Seino Y
    Prog Biophys Mol Biol; 2011 Nov; 107(2):248-56. PubMed ID: 21820006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GIP and GLP-1, the two incretin hormones: Similarities and differences.
    Seino Y; Fukushima M; Yabe D
    J Diabetes Investig; 2010 Apr; 1(1-2):8-23. PubMed ID: 24843404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management.
    Chetty AK; Rafi E; Bellini NJ; Buchholz N; Isaacs D
    Endocr Pract; 2024 Mar; 30(3):292-303. PubMed ID: 38122931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice.
    Liskiewicz A; Khalil A; Liskiewicz D; Novikoff A; Grandl G; Maity-Kumar G; Gutgesell RM; Bakhti M; Bastidas-Ponce A; Czarnecki O; Makris K; Lickert H; Feuchtinger A; Tost M; Coupland C; Ständer L; Akindehin S; Prakash S; Abrar F; Castelino RL; He Y; Knerr PJ; Yang B; Hogendorf WFJ; Zhang S; Hofmann SM; Finan B; DiMarchi RD; Tschöp MH; Douros JD; Müller TD
    Nat Metab; 2023 Dec; 5(12):2075-2085. PubMed ID: 37946085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.